RAPT Therapeutics RAPT Stock
RAPT Therapeutics Price Chart
RAPT Therapeutics RAPT Financial and Trading Overview
| RAPT Therapeutics stock price | 58.02 USD |
| Previous Close | 58.02 USD |
| Open | 57.98 USD |
| Bid | 41.75 USD x 200 |
| Ask | 74.24 USD x 200 |
| Day's Range | 57.98 - 58.02 USD |
| 52 Week Range | 5.67 - 58.02 USD |
| Volume | 11.07M USD |
| Avg. Volume | 2.4M USD |
| Market Cap | 1.68B USD |
| Beta (5Y Monthly) | 0.443 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58 USD |
RAPT Valuation Measures
| Enterprise Value | 1.45B USD |
| Trailing P/E | N/A |
| Forward P/E | -21.383318 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 6.4345126 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -13.013 |
Trading Information
RAPT Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.443 |
| 52-Week Change | 480.05% |
| S&P500 52-Week Change | 27.95% |
| 52 Week High | 58.02 USD |
| 52 Week Low | 5.67 USD |
| 50-Day Moving Average | 49.94 USD |
| 200-Day Moving Average | 27.42 USD |
RAPT Share Statistics
| Avg. Volume (3 month) | 2.4M USD |
| Avg. Daily Volume (10-Days) | 3.1K USD |
| Shares Outstanding | 28.96M |
| Float | 16.85M |
| Short Ratio | 0.42 |
| % Held by Insiders | 0.27% |
| % Held by Institutions | 110.56% |
| Shares Short | 2.24M |
| Short % of Float | 8.58% |
| Short % of Shares Outstanding | 7.73% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:8 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | September 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -51.34% |
| Return on Equity (ttm) | -85.36% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -111664000 USD |
| Net Income Avi to Common (ttm) | -105637000 USD |
| Diluted EPS (ttm) | -11.66 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 157.34M USD |
| Total Cash Per Share (mrq) | 5.68 USD |
| Total Debt (mrq) | 2.6M USD |
| Total Debt/Equity (mrq) | 1.71 USD |
| Current Ratio (mrq) | 12.041 |
| Book Value Per Share (mrq) | 9.017 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -86580000 USD |
| Levered Free Cash Flow (ttm) | -46387500 USD |
Profile of RAPT Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 561 Eccles Avenue |
| ZIP | 94080 |
| Phone | 650-489-9000 |
| Website | https://www.rapt.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 60 |
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.
Q&A For RAPT Therapeutics Stock
What is a current RAPT stock price?
RAPT Therapeutics RAPT stock price today per share is 58.02 USD.
How to purchase RAPT Therapeutics stock?
You can buy RAPT shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for RAPT Therapeutics?
The stock symbol or ticker of RAPT Therapeutics is RAPT.
Which industry does the RAPT Therapeutics company belong to?
The RAPT Therapeutics industry is Biotechnology.
How many shares does RAPT Therapeutics have in circulation?
The max supply of RAPT Therapeutics shares is 28.96M.
What is RAPT Therapeutics Price to Earnings Ratio (PE Ratio)?
RAPT Therapeutics PE Ratio is 0.00000000 now.
What was RAPT Therapeutics earnings per share over the trailing 12 months (TTM)?
RAPT Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the RAPT Therapeutics company belong to?
The RAPT Therapeutics sector is Healthcare.
RAPT Therapeutics RAPT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}